Elsevier

Neuropharmacology

Volume 48, Issue 1, January 2005, Pages 80-92
Neuropharmacology

Interaction of corticosterone and nicotine in regulation of prepulse inhibition in mice

https://doi.org/10.1016/j.neuropharm.2004.08.015Get rights and content

Abstract

The aim of the present study was to investigate if different levels of circulating corticosterone (CORT) modulate the effect of nicotine on prepulse inhibition (PPI), a measure of sensorimotor gating that is disrupted in schizophrenia and other mental illnesses.

Four groups of mice were investigated: sham-operated, adrenalectomized (ADX) and implanted with a cholesterol pellet, ADX and implanted with a 10 mg CORT pellet, or ADX and 50 mg of CORT. Different CORT levels or doses of nicotine did not significantly affect startle responses. Baseline PPI was significantly reduced in mice implanted with the highest dose of CORT. In ADX mice implanted with cholesterol, nicotine treatment influenced PPI depending on the prepulse intensity. In ADX mice implanted with 50 mg of CORT, treatment with 10 mg/kg of nicotine caused a significant increase in PPI at all prepulse intensities.

Binding studies showed that corticosterone treatment had significantly affected nicotinic acetylcholine receptor (nAChR) density in the mouse brain. Treatment with 50 mg CORT decreased 125I-epibatidine binding in the globus pallidus and 125I-α-bungarotoxin binding in the claustrum. These results suggest a possible interaction of corticosterone and nicotine at the level of the α4- and α7-type nAChR in the regulation of PPI. In situations of high circulating levels of corticosterone, nicotine may be beneficial to restore disruption of PPI.

Introduction

The involvement of stress in psychiatric illness, especially schizophrenia and bipolar disorder, is well accepted. For example, there appears to be a clear correlation between stressful life events and relapse frequency in schizophrenic patients (Birley and Brown, 1970) and relatively minor stressors may be predictive of relapse susceptibility (Norman and Malla, 1994). Additionally, there is some evidence for the involvement of stress in the onset of psychosis (Gruen and Baron, 1984) and stress reduction, through intervention, social skill training and education has also been found to be of benefit in the treatment of schizophrenia (Falloon, 1992, Liberman et al., 1986).

Despite this well-established connection, the mechanism by which stress affects schizophrenia is unknown. Schizophrenic patients display abnormalities in the autonomic nervous system (ANS) and hypothalamic-pituitary-adrenal (HPA) axis, suggesting these patients may have an altered susceptibility and response to stress. Disruptions observed in the ANS of schizophrenic patients, such as increased basal heart rate (Gruzelier and Venables, 1975), high skin conductance (Kim et al., 1993) and high systolic blood pressure (Gruzelier and Venables, 1975), suggest that patients may be in a high state of arousal. Abnormalities reported in the HPA of schizophrenic patients are less clear, with studies reporting both normal (Van Cauter et al., 1991) and increased (Whalley et al., 1989) basal cortisol levels and correlating cortisol levels with both negative (Tandon et al., 1991) and positive symptoms (Keshavan et al., 1989).

There is also a strong link between schizophrenia and nicotine. This link was first suggested with the observation of very high rates of smoking among the mentally ill. The incidence of smoking in this group is approximately 60% compared to 25% in the general population. This rate is highest in schizophrenia, where smoking prevalence has been estimated at up to 90% (de Leon et al., 1995). A number of possible reasons for the high incidence of continued smoking among schizophrenics have been proposed. Clinical studies have shown smoking improves processing of auditory stimuli (sensory gating) in patients with schizophrenia, and is known to lessen negative symptoms by increasing dopamine release in the frontal cortex (Lyon, 1999). As cessation of smoking causes a worsening of schizophrenic symptoms, it has been suggested that smoking is a form of self-medication (Dalack et al., 1999). Nicotinic acetylcholine receptors (nAChRs) are pentameric receptors consisting of a combination of α and β subunits. In mammalian brain two of the most common nAChR subtypes are the heteropentameric α4β2 and homopentameric α7 subtypes (Leonard and Bertrand, 2001). A role for nAChRs in schizophrenia is suggested by aberrations in receptor regulation and number observed in schizophrenic brains. Post-mortem studies have shown a reduction in the expression of the α7 subtype in hippocampus (Freedman et al., 1995), frontal cortex (Guan et al., 1999) and thalamus (Court et al., 1999) of patients with schizophrenia. Similarly, α4β2 binding has been found to be reduced in the hippocampus, caudate and cortex of schizophrenic patients (Breese et al., 2000).

Deficits in gating of sensory stimuli displayed by patients with schizophrenia (Braff et al., 1999, Kumari et al., 2002) and bipolar disorder (Franks et al., 1983) can be measured with prepulse inhibition (PPI), which measures the ability of a weak prepulse to inhibit the reflexive startle response to a powerful sensory stimulus (Braff et al., 1999, Geyer et al., 2001). Deficiencies in sensory gating may lead to the sensory flooding and disturbed thought processes characteristic of schizophrenia. Because PPI of acoustic startle can be measured similarly in humans and experimental animals, it provides a unique opportunity to investigate central neurotransmitter mechanisms involved in sensory gating. There is substantial biochemical, pharmacological and genetic evidence for a nicotinic component of disrupted sensory gating, likely involving the α7-typenAChR. Injection of α7 antisense oligonucleotides into the lateral ventricles of rats caused a 40% decrease of α-bungarotoxin binding, indicative of α7 nAChR subtype expression, and abolished PPI responses (Leonard et al., 1996, Rollins et al., 1993). Sensory gating deficits have also been observed in rats following α-bungarotoxin and methyllycaconitine administration, both potent α7 nAChR antagonists (Luntz-Leybman et al., 1992, Rollins et al., 1993). A role for the α7 nAChR in schizophrenia is also supported by genetic evidence, as a sensory gating defect in schizophrenic patients and their first-degree relatives has been linked to a dinucleotide polymorphism at chromosome 15q13-14, the site of the α7 nAChR subunit (Freedman et al., 1997). Inbred mouse strains have also been shown to have differing degrees of PPI. Bullock and colleagues (Joels et al., 1997) examined PPI in six inbred mouse strains and found a significant correlation between levels of α-bungarotoxin binding in the hippocampus and degree of PPI.

Nicotine and stress may interact to affect PPI. It has been repeatedly shown that high dose corticosterone treatment leads to a decrease in α-bungarotoxin binding in a number of brain regions, an effect observed in both radioligand binding assays (Robinson et al., 1996, Stitzel et al., 1996a) and autoradiographical studies (Pauly and Collins, 1993). Reports of corticosterone effects on 3H-nicotine binding have been conflicting with both a small decrease (Pauly and Collins, 1993) and no effect (Robinson et al., 1996) reported. There is also evidence that corticosterone affects nAChR function, as chronic corticosterone treatment produced tolerance to nicotine (Robinson et al., 1996) and affected nAChR affinity (Ke and Lukas, 1996, von Euler et al., 1990). Stress has been shown to directly affect nAChR levels, with immobilization stress leading to decreases in 3H-cytisine binding (Takita and Muramatsu, 1995), indicative of α4-type nAChRs.

Given the evidence for a complex interaction between corticosterone, nicotine and PPI and the importance of these factors in schizophrenia, the aims of this study were to further investigate the effect of different levels of circulating corticosterone on the acute action of nicotine treatment on PPI and on the number and distribution of α7-type and α4β2-type nAChRs using receptor autoradiography.

Section snippets

Methods

We used male C57BL/6J mice obtained from Animal Resources Centre, Perth, Australia, and the breeding colony of the Department of Pathology, University of Melbourne. This latter breeding colony was sourced from the breeding colony of the Animal Resources Centre. After surgery, the animals were housed individually on Fibrecycle bedding and shredded paper in standard plastic mouse cages (l × w × h; 28 × 16 × 10 cm). They received Barastoc GR2 pellet food and tap water ad libitum. The animals were kept in an

Baseline parameters and startle responses

Final body weights of the mice showed significant differences between the groups (F(3.43) = 5.33, P = 0.003). Bonferroni-corrected t-test showed that body weights were significantly lower in ADX mice implanted with a 50 mg CORT pellet compared to sham-operated mice and to ADX mice implanted with a cholesterol pellet (Table 1). There were also significant group differences in spleen weights (F(3,43) = 25.9, P < 0.001) and spleen/body weight ratios (F(3,43) = 12.2, P < 0.001). Compared to sham-operated mice,

Discussion

The major finding of the present study is that chronic treatment with high dose corticosterone reduces prepulse inhibition in mice and that this disruption can be improved with acute high dose nicotine treatment. There was a significant difference between the ADX group chronically treated with cholesterol and the ADX group chronically treated with 50 mg of CORT, indicating there may be an interaction occurring between nicotine and the presence/absence of corticosterone. These data largely

Acknowledgements

Dr. van den Buuse was supported by the Griffith Fellowship of the University of Melbourne. Parts of the study were supported by the National Health and Medical Research Council of Australia.

References (62)

  • M.H. Kodsi et al.

    Regulation of prepulse inhibition by ventral pallidal projections

    Brain Research Bulletin

    (1997)
  • V. Kumari et al.

    Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics

    Schizophrenia Research

    (2002)
  • C. Lammers et al.

    Regulation of striatal dopamine receptors by corticosterone: an in vivo and in vitro study

    Molecular Brain Research

    (1999)
  • V. Luntz-Leybman et al.

    Cholinergic gating of response to auditory stimuli in rat hippocampus

    Brain Research

    (1992)
  • M.J. Marks et al.

    ST/b and DBA/2 mice differ in brain alpha-bungarotoxin binding and alpha 7 nicotinic receptor subunit mRNA levels: a quantitative autoradiographic analysis

    Molecular Brain Research

    (1996)
  • J.S. Meyer et al.

    Subcutaneous implantation method for chronic glucocorticoid replacement therapy

    Physiology and Behaviour

    (1979)
  • J.R. Pauly et al.

    Strain differences in adrenalectomy-induced alterations in nicotine sensitivity in the mouse

    Pharmacology Biochemistry and Behaviour

    (1990)
  • S.F. Robinson et al.

    Changes in sensitivity to nicotine and brain nicotinic receptors following chronic nicotine and corticosterone treatments in mice

    Pharmacology Biochemistry and Behaviour

    (1996)
  • K.E. Stevens et al.

    Chronic corticosterone treatment alters sensory gating in C3H mice

    Pharmacology Biochemistry and Behaviour

    (2001)
  • J.A. Stitzel et al.

    Chronic corticosterone treatment elicits dose-dependent changes in mouse brain alpha-bungarotoxin binding

    Neuroscience

    (1996)
  • J.A. Stitzel et al.

    Linkage of strain-specific nicotinic receptor alpha 7 subunit restriction fragment length polymorphisms with levels of alpha-bungarotoxin binding in brain

    Molecular Brain Research

    (1996)
  • H. Takahashi et al.

    Extracellular serotonin in the striatum increased after immobilization stress only in the nighttime

    Behavioural Brain Research

    (1998)
  • M. Takita et al.

    Alteration of brain nicotinic receptors induced by immobilization stress and nicotine in rats

    Brain Research

    (1995)
  • R. Tandon et al.

    Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome

    Biological Psychiatry

    (1991)
  • J.L. Birley et al.

    Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects

    British Journal of Psychiatry

    (1970)
  • D.L. Braff et al.

    Symptom correlates of prepulse inhibition deficits in male schizophrenic patients

    American Journal of Psychiatry

    (1999)
  • H.U. Bryant et al.

    Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment

    Endocrinology

    (1991)
  • A.E. Bullock et al.

    Inbred mouse strains differ in the regulation of startle and prepulse inhibition of the startle response

    Behavioural Neuroscience

    (1997)
  • M. van den Buuse et al.

    Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice

    British Journal of Pharmacology

    (2004)
  • J. Court et al.

    Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus

    Journal of Neurochemistry

    (1999)
  • I.R. Falloon

    Early intervention for first episodes of schizophrenia: a preliminary exploration

    Psychiatry

    (1992)
  • Cited by (17)

    • Psychosis and synthetic cannabinoids

      2018, Psychiatry Research
      Citation Excerpt :

      It has been hypothesized that cannabinoid agonists moderate cortisol release, which might explain these inconsistent results (Avdesh et al., 2012; Brown and Dobs, 2002; Quednow et al., 2004). Like cannabinoid agonists, chronic corticosterone exposure has been shown to impair PPI in a similar manner in mice (Ingram et al., 2005; Stevens et al., 2001). The variety of effects of cannabinoid agonists may depend on a mix of corticosteroid dependent and independent actions and may be contingent on viewing the effects on PPI through either stimulus potency or response capacity gating (Avdesh et al., 2012).

    • Review of endocrine disorders associated with environmental toxicants and possible involved mechanisms

      2016, Life Sciences
      Citation Excerpt :

      In case of stress, elevated glucocorticoid levels exert change in HPA axis causing schizophrenia [90]. An altered concentration of corticosterone in animal studies has also been reported to exert change in the HPA axis, ultimately raising more chances of schizophrenia [91,92]. EDC directly target many neuro-steroids like allopregnenolone that regulate mechanism evoking psychiatric disorders.

    • Gene-environment interaction of reelin and stress in cognitive behaviours in mice: Implications for schizophrenia

      2015, Behavioural Brain Research
      Citation Excerpt :

      Instead, CORT treatment significantly reduced PPI in male WT mice, whereas it had no effect in male HRM. Reduced PPI in male WT mice after CORT administration has been previously reported [49]. To the best of our knowledge, this is the first study investigating CORT effect on PPI in HRM.

    • D-serine prevents cognitive deficits induced by acute stress

      2014, Neuropharmacology
      Citation Excerpt :

      If this was the case, one would expect that co-agonist administration could prevent other cognitive deficits associated to acute stress. Stress signaling impairs the PPI response (Ingram et al., 2005; Richter et al., 2011; Sutherland and Conti, 2011), a type of brain response dependent on NMDAR function (Bakshi and Geyer, 1998). Studies in humans observed a detrimental effect of NMDAR antagonists in the PPI response (Oranje et al., 2002; van Berckel et al., 1998).

    View all citing articles on Scopus
    View full text